Skip to content
Screener

Stoke Therapeutics, Inc. STOK Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Revenue$1.4MMiss by $4.4M
EPS-$0.97Miss by $0.22
Revenue estimate$5.8M
EPS estimate-$0.75

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.2M
EPS estimate-$0.88

Financials

Q4 2025

Income statement

See full
Revenue$1.4M-93.8%
Operating income-$61.4M-350%
Net income-$57.9M-453%
EPS (diluted)-$0.97-471%

Balance sheet

See full
Cash & equivalents$84.2M-34.2%
Total debt$4.1M-13.1%
Total equity$352.5M+53.9%
Total assets$418.4M+54.1%

Cash flow

See full
CapEx$232.0K+452%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.81B+210%
Enterprise value$1.73B+276%
P/S9.8×-6.2×

Profitability

See full
Operating margin-11.2%-5.5pp
Net margin-3.7%-1.9pp

Returns & leverage

See full
Return on equity-2.4%-1.2pp
Debt / equity0×0.0×
Current ratio5.3×-0.5×

FAQ

When did Stoke Therapeutics, Inc. report Q4 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q4 2025 earnings on March 16, 2026 before market open.
What were Stoke Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $1.4M and eps of $-0.97 for Q4 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $5.8M by $4.4M. EPS missed the consensus estimate of $-0.75 by $0.22.
How did Stoke Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 93.8% from $22.6M a year earlier and eps declined 438.9% from $-0.18.
Where can I find Stoke Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 10-K periodic report (0001193125-26-108362) directly on SEC EDGAR. The filing index links above go to sec.gov.